In The Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application:

1-15. (canceled)

16. (currently amended) A method for treatment ~~or prophylaxis~~ of a solid cancerous tumor in a mammal wherein a composition of formula I ~~Claim 10~~ is administered to said mammal in a dosage sufficient to damage new vasculature but insufficient to exhibit anti-mitotic activity:



I

wherein:

alk is an alkyl group;

X is oxygen, sulfur, sulphinyl, sulphonyl, carbonyl (CO), thiocarbonyl (CS), sulphonyloxy, NH, iminomethylene (C=NH), N-hydroxyiminomethylene, N-alkoxyiminomethylene, dialkoxymethylene, 1,3-dioxolan-2y1, 1,1-ethenyl, a group CHR^3 or a bond;

R^1 is hydrogen, alkylaminocarbonyl or alkoxycarbonyl;

R^2 is hydrogen, alkoxycarbonyl, cyanomethyl, cyanoethyl, alkoxymethyl or acetoxymethyl;

R^3 is hydrogen, hydroxy, alkoxy or amino;

A is a substituted aromatic~~, substituted heteroaromatic, substituted heterocycloalkyl,~~ or substituted alkyl ~~or substituted cycloalkyl~~ group; wherein the substituent on A is selected from phosphate, alkylphosphate, $NHC(O)R^4$, $NR^5C(O)R^4$,

~~(a) alkyl substituted by one or more of hydroxy, amino, alkylamino, dialkylamino, halogen, carboxyl, SO_3H, sulfate, phosphate, alkoxycarbonyl, aralkoxycarbonyl, alkoxycarbonylamino, aminoalkylaminocarbonyl, alkoxy, alkylthio, cyano, nitro, isothiocyanate, aryl, heteroaryl and heterocycloalkyl; or~~

~~(b) a group Y selected from phosphate, alkylphosphate, $C(O)R^4$, $OC(O)R^4$, $S0_2R^4$, $NHC(O)R^4$, $NR^5C(O)R^4$, SR^4, $S(O)R^4$, $0S0_2R^4$, $NHSO_2R^4$, NR^5SO_2R4, SO_3H, CO_2H and $C0_2R^5$;~~

~~where R^4 is selected from hydrogen, R^5, OR^5, NHR^5, NR^5R^6, aryl, heteroaryl and heterocycloalkyl, such aryl, heteroaryl or heterocycloalkyl groups being optionally substituted with one or more substituents selected from alkyl, heterocycloalkyl, haloalkyl, hydroxy, nitro, cyano, amino, alkylamino, dialkylamino, halogen, carboxyl, SO_3H, sulfate and phosphate; and wherein R^5 and R^6, which may be the same or different, are each an alkyl group substituted with one or more substituents selected from hydroxy, amino, alkylamino, dialkylamino, guanidino, halogen, carboxyl, SO_3H, sulfate, phosphate, aryl and heteroaryl~~

R^4 and R^5, which may be the same or different, are each an alkyl group substituted with one or more substituents selected from hydroxy, amino, alkylamino, guanidino, carboxyl, SO_3H, sulfate and phosphate; and

prodrugs and pharmaceutically acceptable salts, solvates and hydrates thereof.

17. (previously presented) The method of Claim 16 wherein said composition is administered in the range of about 0.001 to about 100 mg/kg body weight.

18. (previously added). The method of Claim 16 wherein said composition is administered in the range of about 0.1 to about 50 mg/kg body weight.

19-30. (canceled)

31. (previously presented) A method according to Claim 16 further comprising the simultaneous or sequential administration of one or more of a mitotic inhibitor, an alkylating agent, an antimetabolite, an intercalating agent, an enzyme, a topoisomerase inhibitor, a thymidylate synthase inhibitor, a biological response modifier, an antibody, an anti-hormone, or any combination thereof.

32. (previously presented) A method according to Claim 31 wherein said mitotic inhibitor comprises at least one of vinblastine, paclitaxel, docetaxel, or any combination thereof.

33. (previously presented) A method according to Claim 31 wherein said alkylating agent comprises at least one of cisplatin, carboplatin, cyclophosphamide, or any combination thereof.

34. (previously presented) A method according to Claim 31 wherein said antimetabolite comprises at least one of 5-fluorouracil, cytosine arabinoside, hydroxyurea, or any combination thereof.

35. (previously presented) A method according to Claim 31 wherein said intercalating agent comprises at least one of adriamycin, bleomycin, or any combination thereof.

36. (previously presented) A method according to Claim 31 wherein said enzyme comprises aspariginase.

37. (previously presented) A method according to Claim 31 wherein said topoisomerase inhibitor comprises at least one of etoposide, topotecan, irinotecan, or any combination thereof.

38. (previously presented) A method according to Claim 31 wherein said thymidylate synthase inhibitor comprises raltitrexed.

39. (previously presented) A method according to Claim 31 wherein said biological response modifier comprises interferon.

40. (previously presented) A method according to Claim 31 wherein said antibody comprises at least one of edrecolomab and antibodies against the EGFr, HER2 receptor or VEGF receptor, or any combination thereof.

41. (previously presented) A method according to Claim 31 wherein said anti-hormone comprises tamoxifen.